Pluristem Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics

PSTI 8.720

+0.2%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: xcentral1	10/13/2010 8:39:08 AM
	of 295

BRIEF: Pluristem raises $5.25m from institutional, private investors Oct 12, 2010 -- Stem cell company Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT) has raised $5.25 million from institutional and private investors in Israel and the US. One of the investors is former Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) VP Ami Rosenfeld. Pluristem's share is currently being traded at $1.39 on Nasdaq giving a market cap of $30.34 million. The investment will help the company reach the $35 million market cap threshold to dual list on the TASE, although the company has still not officially said that it will do so. Pluristem chairman, president and CEO Zami Aberman said that the money raised will be used to push forward the company's clinical trials. Last month the company reported positive results for a clinical trial for cell therapies derived from human placenta on 21 patients suffering from critical limb ischemia (CLI). The patients had improved blood flow to their legs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next